Tag

Aurlumyn

All articles tagged with #aurlumyn

health2 years ago•2 min saved

"FDA Approves First Medication to Prevent Frostbite Amputation"

The FDA has approved Aurlumyn (iloprost) injection as a treatment for severe frostbite in adults to reduce the risk of finger or toe amputation. Iloprost, the active ingredient, is a vasodilator that prevents blood clotting. This approval provides the first-ever treatment option for severe frostbite in the United States, offering a significant advancement in frostbite treatment. Existing clot-bursting medications come with high risks and are effective for only around 24 hours post-frostbite, while iloprost has been used safely and effectively in other countries for years.

via Good News Network|

#amputation #aurlumyn #fda

health2 years ago•2 min saved

"FDA Approves First Frostbite Drug Aurlumyn to Prevent Amputations"

The FDA has approved Aurlumyn, the first drug designed to prevent limb amputation from severe frostbite. The drug, developed by Eicos Sciences, showed significant reduction in the risk of amputation in a clinical trial compared to standard care. Aurlumyn, an intravenous drug containing iloprost, is intended to open up blood vessels and prevent clots that can cause permanent damage. While severe frostbite is rare, the drug will benefit groups regularly exposed to extreme cold, such as mountain climbers, military personnel, and homeless populations.

via Gizmodo|

#aurlumyn #fda-approval #frostbite

health2 years ago•1 min saved

"Breakthrough Drug Aurlumyn Offers Hope for Frostbite Amputation Prevention"

The FDA has approved the first medication for treating severe frostbite in adults, a condition that can lead to amputations. The injectable drug, Aurlumyn, made by Eicos Sciences, contains iloprost, a vasodilator that opens blood vessels and prevents clotting. Severe frostbite, caused by exposure to freezing temperatures, can lead to disabled patients and disproportionately affects the homeless population. In a clinical trial, none of the patients who received only the new drug required amputations, compared to those who received other medications. Aurlumyn is expected to be available this spring, with the price yet to be determined.

via The Washington Post|

#aurlumyn #fda #frostbite

health2 years ago•2 min saved

"FDA Approves First Drug for Severe Frostbite"

The FDA has approved the first medication, iloprost (brand name Aurlumyn), to treat severe frostbite, reducing the risk of finger and toe amputations due to dangerously cold extremities. This vasodilator drug, originally approved for pulmonary arterial hypertension, prevents blood clotting and preserves blood flow, as shown in a clinical trial where patients who received iloprost did not require amputation. Developed by Eicos Sciences Inc., the drug may cause side effects and must be administered by a physician.

via New York Post |

#aurlumyn #fda #frostbite

health2 years ago•3 min saved

"FDA Grants First-Ever Approval for Severe Frostbite Medication"

The FDA has approved the first medication, iloprost (brand name Aurlumyn), to treat severe frostbite, aiming to reduce the risk of finger and toe amputations due to dangerously cold extremities. Iloprost, originally approved for pulmonary arterial hypertension, is a vasodilator that preserves blood flow and prevents clotting in the affected areas. In a clinical trial, patients who received iloprost did not require amputation, unlike those who received other medications. However, the drug may cause side effects and must be administered by a physician.

via Fox News|

#aurlumyn #fda #frostbite

health2 years ago•2 min saved

"FDA Greenlights First Drug for Severe Frostbite Treatment"

The FDA has approved Aurlumyn, the first medication to treat severe frostbite in adults, manufactured by Actelion Pharmaceuticals US, Inc. Frostbite is an injury caused by cold temperatures, and severe cases can lead to amputation. Aurlumyn, containing the active ingredient iloprost, is a vasodilator that helps improve blood flow and prevent clotting. In a controlled trial, patients receiving Aurlumyn had lower rates of amputation compared to those receiving unapproved medications. Common side effects include flushing, headache, nausea, and dizziness.

via ABC News|

#actelion-pharmaceuticals #aurlumyn #fda